Lantus and Finasteride Interaction: What Prescribers and Patients Should Know

Why This Combination Comes Up in Clinical Practice

Men with type 2 diabetes frequently also carry diagnoses that call for finasteride. Benign prostatic hyperplasia (BPH) affects roughly 50% of men by age 60, and androgenetic alopecia is similarly common 1. Because insulin glargine is one of the most prescribed basal insulins worldwide, with over 20 million U.S. prescriptions dispensed annually 2, the overlap between these two patient populations is large.

The good news is straightforward. These drugs operate through completely independent pharmacologic pathways. No case reports, no pharmacovigilance signals, and no controlled trials have identified a clinically meaningful interaction between insulin glargine and finasteride. The remainder of this article explains the mechanistic basis for that safety profile, addresses secondary metabolic considerations around androgens and glucose homeostasis, and provides practical monitoring guidance.

Pharmacokinetic Independence: Separate Metabolic Pathways

Insulin glargine and finasteride never compete for the same metabolic enzymes, transport proteins, or binding sites. This pharmacokinetic independence is the primary reason the combination is considered safe.

Insulin glargine is a recombinant human insulin analog. After subcutaneous injection, it forms microprecipitates in the neutral pH of subcutaneous tissue, then slowly dissolves and enters the bloodstream 2. Circulating insulin glargine is cleaved by tissue peptidases and endosomal proteases into active metabolites M1 and M2. The drug never enters the hepatic cytochrome P450 system. It has no interaction with P-glycoprotein (P-gp) transporters. The FDA prescribing information for Lantus states: "Drug interaction studies have not been performed. Based on the mechanism of action, no CYP-mediated drug interactions are expected" 2.

Finasteride, by contrast, is an oral small molecule metabolized in the liver. CYP3A4 is the primary enzyme responsible for its oxidative biotransformation, with minor contributions from CYP3A5 3. Finasteride does not inhibit or induce any major CYP isoforms at therapeutic doses (1 mg for hair loss, 5 mg for BPH). It has no clinically relevant effect on P-gp. The Proscar label notes that "no drug interactions of clinical importance have been identified" 3.

Because one drug is degraded by peptidases and the other by CYP3A4, there is zero metabolic overlap.

Pharmacodynamic Considerations: Androgens, DHT, and Glucose

The more nuanced question is whether finasteride's effect on androgen metabolism could indirectly alter glycemic control. This requires a closer look at what finasteride does to the androgen axis and what androgens do to insulin sensitivity.

Finasteride inhibits type II 5-alpha reductase, blocking the conversion of testosterone to dihydrotestosterone (DHT). In men taking finasteride 5 mg daily for BPH, serum DHT decreases by approximately 70%, while serum testosterone rises by roughly 10 to 20% 3. At the 1 mg dose for alopecia, the DHT reduction is about 65%, with a smaller testosterone increase 4.

A 2011 meta-analysis by Corona et al. (47 studies, N=3,029 hypogonadal men) demonstrated that testosterone therapy was associated with a reduction in fasting glucose of 0.61 mmol/L (95% CI: 0.33 to 0.90) and a decrease in HOMA-IR of 1.03 (95% CI: 0.57 to 1.50) 5. These data suggest that higher testosterone levels generally improve insulin sensitivity.

The testosterone increase produced by finasteride is modest compared to exogenous testosterone replacement. A 10 to 20% rise from a baseline of, say, 400 ng/dL would bring levels to 440 to 480 ng/dL. This is within normal physiologic range and unlikely to produce a measurable change in insulin requirements.

One area that has received attention is whether 5-alpha reductase inhibition itself might worsen metabolic parameters independent of the testosterone effect. Upreti et al. (2014) published a systematic review examining metabolic outcomes in men taking 5-alpha reductase inhibitors. They found that finasteride and dutasteride were associated with small increases in fat mass in some cohorts, but the effect on fasting glucose and HbA1c was inconsistent across studies 6. The clinical significance of these changes remains unclear and is unlikely to alter basal insulin dosing.

What Drug Interaction Databases Say

Prescribers often rely on electronic drug interaction checkers embedded in EHR systems. These tools assign severity ratings based on published evidence and pharmacologic plausibility.

No interaction is listed between insulin glargine and finasteride in any of the three major commercial databases (Lexicomp, Micromedex, Clinical Pharmacology). The Drugs.com interaction checker, which aggregates multiple sources, returns "no known interaction" for this pair 7. The American Diabetes Association (ADA) Standards of Care do not list 5-alpha reductase inhibitors among drug classes requiring insulin dose modification 8.

Dr. Irl Hirsch, professor of medicine at the University of Washington, has written extensively on insulin drug interactions. In a 2019 review in Diabetes Care, Hirsch and colleagues noted: "The drugs most likely to alter insulin requirements are those with direct glucoregulatory effects, including corticosteroids, thiazide diuretics, atypical antipsyctics, and certain antiretrovirals. Medications without glucose-active mechanisms rarely necessitate insulin adjustment" 9.

Finasteride does not appear in any published list of drugs that alter insulin requirements.

Drugs That Do Interact with Insulin Glargine

To put the finasteride question in perspective, consider the medications that genuinely do require insulin dose adjustments. Understanding the contrast makes the safety of the finasteride combination clearer.

Drugs that increase hypoglycemia risk when combined with insulin glargine include sulfonylureas (glipizide, glyburide), GLP-1 receptor agonists (semaglutide, liraglutide), ACE inhibitors, beta-blockers (which may also mask hypoglycemic symptoms), and salicylates at anti-inflammatory doses 2. The ORIGIN trial (N=12,537) demonstrated that insulin glargine combined with sulfonylureas increased confirmed hypoglycemia rates to 1.00 events per patient-year compared to 0.31 in the standard-care arm 10.

Drugs that can raise blood glucose and blunt insulin efficacy include systemic corticosteroids (prednisone, dexamethasone), atypical antipsychotics (olanzapine, clozapine), protease inhibitors, and thiazide diuretics 2. These classes require proactive insulin titration, sometimes within 24 to 48 hours of initiation.

Finasteride belongs to neither category. It has no known effect on pancreatic beta-cell function, hepatic glucose output, peripheral glucose uptake, or counter-regulatory hormone secretion.

Blood Glucose Monitoring Guidance

Even when no pharmacologic interaction exists, the ADA recommends enhanced self-monitoring of blood glucose (SMBG) for 7 to 14 days whenever a patient on insulin starts any new medication 8. This is a general safety principle, not specific to finasteride.

Practical monitoring steps for patients starting finasteride while on Lantus:

• Continue the current Lantus dose without preemptive changes.
• Check fasting blood glucose each morning for two weeks.
• Log any readings below 70 mg/dL or above 180 mg/dL.
• Report patterns of two or more out-of-range readings in a week to the prescribing physician.
• If using a continuous glucose monitor (CGM), review the ambulatory glucose profile (AGP) after 14 days for any change in time-in-range (TIR).

There is no expectation that finasteride will shift these parameters. The monitoring is precautionary and aligns with standard diabetes management.

Special Populations: Men with Type 2 Diabetes and Hypogonadism

A subgroup worth discussing is men who have both type 2 diabetes and symptomatic hypogonadism. Testosterone deficiency is highly prevalent in this population. The EMAS study found that 17% of men with type 2 diabetes had total testosterone below 230 ng/dL, compared to 6% of age-matched controls 11.

For these men, finasteride is sometimes prescribed alongside testosterone replacement therapy (TRT) to mitigate DHT-driven side effects like prostate enlargement or hair thinning. In this scenario, the patient may be taking insulin glargine, exogenous testosterone, and finasteride simultaneously.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, evaluated cardiovascular safety of testosterone replacement in men with hypogonadism and established cardiovascular disease or high cardiometabolic risk. TRAVERSE found no increase in major adverse cardiovascular events (MACE) with testosterone gel versus placebo (HR 0.99 to 95% CI: 0.81 to 1.21) 12. Among the diabetic subgroup, HbA1c did not differ significantly between arms.

When all three medications are used together, the interaction profile remains predictable. Testosterone itself may modestly improve insulin sensitivity (per the Corona meta-analysis), finasteride modulates the androgen axis without glucoregulatory effects, and insulin glargine is metabolized independently of both.

Finasteride Side Effects That May Mimic or Confuse Diabetes Symptoms

Though no drug interaction exists, prescribers should be aware that some finasteride side effects can overlap with symptoms patients might attribute to blood glucose fluctuations.

Fatigue, reported in 2 to 5% of men on finasteride 5 mg, can mimic hypoglycemia-related tiredness 3. Dizziness, while rare with finasteride, is commonly associated with both hypo- and hyperglycemia. Mood changes, reported in post-marketing data for finasteride, may overlap with the emotional lability some patients experience during glucose excursions.

Patients on both medications should be counseled to check blood glucose before attributing symptoms to either drug. A fingerstick reading takes 10 seconds and eliminates diagnostic ambiguity.

When to Involve the Prescriber

No routine dose adjustment or specialist referral is needed for the insulin glargine and finasteride combination. Contact the prescribing physician if any of the following occur:

• Fasting glucose values consistently shift by more than 20% from baseline after starting finasteride (unlikely but warrants investigation for other causes).
• The patient begins or stops testosterone replacement therapy, which has a larger effect on insulin sensitivity than finasteride alone.
• The patient is switched from finasteride to dutasteride, which inhibits both type I and type II 5-alpha reductase and produces a more complete DHT suppression (~90% vs. ~70%). Dutasteride also has no known interaction with insulin, but the broader enzymatic inhibition profile justifies a fresh review.

The Endocrine Society's 2018 guidelines on testosterone therapy in men with hypogonadism recommend: "In patients with diabetes mellitus on insulin, monitor glycemic control after initiation of testosterone therapy and adjust insulin dose as needed" 13. This guidance applies to testosterone itself, not to finasteride, but it provides a relevant framework for managing the broader endocrine context.